Target intelligence / Profile preview

Ariadne RBR E3 ubiquitin protein ligase 2 pseudogene 1 (ARIH2P1)

Target
ARIH2P1
Molecular classification
Other (Pseudogene, Non-coding RNA)
01

Overview

Ariadne RBR E3 ubiquitin protein ligase 2 pseudogene 1 (ARIH2P1) is classified as a pseudogene, meaning it is a nonfunctional segment of DNA that resembles its parent gene (ARIH2, which encodes a ubiquitin ligase protein), but ARIH2P1 itself does not encode a functional protein due to disabling mutations[1][3][5]. Pseudogenes like ARIH2P1 may be transcribed into non-coding RNAs and, in rare cases, participate in gene regulation (such as acting as microRNA decoys or generating regulatory RNAs), but no evidence is available that ARIH2P1 itself has such functions[2][5]. It is not considered a therapeutic target, does not interact with drugs, and has no known relevance as a disease biomarker or safety concern. Pseudogenes can occasionally complicate genetic studies due to sequence similarity with their functional counterparts[5].

Other names
ARIH2P
02

Mechanism of action

None known (Not a druggable protein, not targeted by small molecules or biologics)

03

Biological functions

Other (No functional protein product; may have non-coding regulatory roles such as miRNA decoy or RNA interference, though no evidence for ARIH2P1 specifically)
04

Disease associations

Other (No direct disease link for ARIH2P1; generally, some pseudogenes may regulate oncogenes/tumor suppressors by non-coding RNA mechanisms, but no evidence for ARIH2P1 involvement in disease)

Beyond the preview

Go deeper on Ariadne RBR E3 ubiquitin protein ligase 2 pseudogene 1 (ARIH2P1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ariadne RBR E3 ubiquitin protein ligase 2 pseudogene 1 (ARIH2P1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call